Background-Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a lethal, rare hereditary disease with an estimated prevalence of 1:10 000. The genetic variants that cause CPVT are usually highly penetrant. To date, about 189 variants in 5 genes (RYR2, CASQ2, CALM1, TRND, and KCNJ2) have been associated with CPVT pathogenesis. Methods and Results-The Exome Sequencing Project database (ESP; n= 6503) was systematically searched for previously published missense and nonsense CPVT-associated variants reported in several comprehensive reviews and in 2 databases: The Human Gene Mutation Database and The Inherited Arrhythmias Database. We used 4 different prediction tools to assess all missense variants previously associated with CPVT and compared the prediction of protein damage between CPVT-associated variants identified in the ESP and those variants not identified in the ESP. We identified 11% of the variants previously associated with CPVT in the ESP population. In the literature, 57% of these variants were reported as novel disease-causing variants absent in the healthy control subjects. These putative CPVT variants were identified in 41 out of 6131 subjects in the ESP population, corresponding to a prevalence of CPVT of up to 1:150. Using an agreement of ≥3, in silico prediction tools showed a significantly higher frequency of damaging variants among the CPVT-associated variants not identified in the ESP database (83%) compared with those variants identified in the ESP (50%; P=0.021). Conclusions-We identified a substantial overrepresentation of CPVT-associated variants in a large exome database, suggesting that these variants are not necessarily the monogenic cause of CPVT. (Circ Cardiovasc Genet. 2013;6:481-489.) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
C atecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited, highly lethal arrhythmogenic cardiac disorder, which is characterized by insidious lethal ventricular arrhythmias in the absence of structural heart disease and with normal electrocardiographic patterns at rest. 1 The prevalence of this rare monogenic disease has been estimated to be approximately 1:10 000. 2 The mean age of onset of CPVT is 8 years, making it a significant cause of sudden death in the young. However, onset as late as 40 years has been reported in rare cases. For untreated patients, the mortality rate is 30% to 50% before 35 years of age. 1 Symptoms occur on exercise or emotional stress from adrenergic mediated ventricular arrhythmias causing syncope, cardiac arrest, and sudden cardiac death. 3 
Clinical Perspective on p 489
CPVT may be underdiagnosed by physicians, and consideration of CPVT has been suggested if the standard cardiac ion channel genetic screening for long QT syndrome (LQTS) turns out negative because CPVT and concealed LQTS may phenotypically mimic one another. 4 To date, no genotype-based risk stratification or differential treatment approach has been suggested based on CPVT-positive variants. However, early genetic testing is recommended by the Heart Rhythm Society and the European Heart Rhythm Association for clinical management and therapeutic decisions involving family members because CPVT may present as Sudden Unexpected Death or Sudden Infant Death Syndrome as the first manifestation. 5, 6 Genetic testing is a valuable tool for diagnosing patients with CPVT and their family members with suspected CPVT, thereby facilitating presymptomatic diagnosis, appropriate counseling, and initiation of prophylactic β-blocker therapy. 5 To date, variants in 5 genes have been associated with CPVT: TRDN (the triadin gene), CALM1 (Calmodulin-1 gene), KCNJ2 (the inward rectifying potassium channel gene), RYR2 (the cardiac ryanodine receptor gene) causing the autosomal dominant form of type 1 CPVT (CPVT1), and CASQ2 (the cardiac calsequestrin gene) causing the autosomal recessive form of type 2 CPVT (CPVT2; Table 1 ). 6 Additionally, 1 locus on chromosome 7p14-22 has been associated with a severe form of autosomal recessive form of CPVT, known as CPVT3 (Table 1) . 2, 7, 8 Of note, the ANK2 (the ankyrin-2) gene is not considered a CPVT gene. 6 Studies are increasingly focusing on separating genetic noise from truly disease-causing variations by identifying variants previously associated with disease in healthy populations. [9] [10] [11] [12] [13] MacRae 14 emphasizes the importance of this approach in a recent editorial; however, to our knowledge, there are no systematic studies exploring this in the field of CPVT.
In 2012, the National Heart, Lung, and Blood Institute Exome Variant Server published the last exome data from the Exome Sequencing Project (ESP; n=6503 individuals) in the Exome Variant Server. The purpose of ESP was to determine the frequency counts of specific variants and to identify novel genetic variants in coding regions of the human genome irrespective of phenotype. Knowledge of the frequency of genetic variations, especially low-frequency variants, is a key gain from the ESP.
In this report, we investigate the frequency of CPVTassociated variants in ESP data and compare the prevalence of these variants with the expected prevalence of CPVT in the same population.
Method

Databases and Population
The current ESP database, also known as ESP6500, contains 2203 African American (AA) and 4300 European American (EA) unrelated individuals (13 006 alleles), representing diverse phenotyped populations. 15 Participants in the ESP were selected to contain healthy controls, the extremes of specific traits (low-density lipoprotein and blood pressure), specific diseases (early onset myocardial infarction and early onset stroke), and lung diseases. No clinical data apart from ethnicity were available in the ESP population, nor were data available on request. 15 The ESP database was systematically searched for previously published CPVT-associated variants reported in comprehensive reviews by Leenhardt et al, 2 Faggioni et al, 7 Medeiros-Domingo et al, 16 Tester et al, 17 and variants in the 2 databases: The Human Gene Mutation Database (HGMD; December, 2012) and The Inherited Arrhythmias Database (FSM; http://www.fsm.it/cardmoc/; December, 2012). A priori, we decided not to include any CPVT-associated variants identified in healthy control subjects in any previously published literature. Furthermore, we did not include variations in ANK2 and KCNJ2 genes in our statistical analysis because there are no recommendations for systematic screening of these genes in patients with CPVT and these genes are more convincingly associated with other inherent arrhythmic diseases, such as Brugada syndrome and Andersen-Tawil syndrome (LQTS). 5, 18, 19 Throughout the text, we refer to those CPVT-associated variants previously identified in the ESP database as ESP-positive variants and those variants not identified in ESP as ESP-negative variants. Because of lack of data on variants positioned in introns and untranslated regions in the ESP, these variants could not be included.
The literature was searched for functional characterization and family cosegregation of all CPVT-associated variants. Cosegregation was defined as ≥2 family members having both the phenotype and the genotype.
Prediction Analysis
All previously reported CPVT-associated missense variants were evaluated with prediction tools.
Protein damage predictions of CPVT-associated variants identified in the ESP were compared with those variants not identified in the ESP.
To predict the possible impact of amino acid substitution, 4 types of prediction tools were used: (1) Conservation across species, (2) Grantham Score, (3) SIFT (Sorting Intolerant From Tolerant, v. 4.05), and (4) PolyPhen-2 (Polymorphism Phenotyping v2). A variant was classified as damaging (D) if ≥3 in silico prediction tools predicted the variant to be pathogenic, as described by Giudicessi et al. 20 A variant was defined as a variant of uncertain significance (VUS) when 1 or 2 of the prediction tools predicted the variant to be damaging and in absence of functional data indicating that the variant might be damaging. A variant was categorized as benign (B) if all 4 prediction tools predicted the variant to be benign. Prediction analyses were only possible for missense variants. Nonsense variants were assumed to be probably damaging.
Further details on the prediction analysis are provided in the Appendix in the online-only Data Supplement.
Differences in proportions of variants predicted to be damaging for those variants identified ESP versus variants not identified in ESP were assessed using Fisher exact test with P<0.05 as statistically significant. The R statistical programming language was used for the statistical analysis.
Results
ESP-Positive Variants
To date, 5 genes have been associated with CPVT: RYR2, CASQ2, CALM1, TRND, and KCNJ2. 6 In RYR2, CASQ2, CALM1, and TRND, we found a total of 188 missense/ nonsense variants and 1 synonymous variant that have been associated with CPVT. Ninety percent (170 out of 189) of the variants were found in RYR2, and 8% (14 missense/nonsense variants and 1 synonymous variant out of 189) of the variants were found in CASQ2 (Table 1 ). In the ESP, we identified 11% (21 out of 189) of previously CPVT-associated variants (of note, variants in ANK2 are not included). These variants are listed in Tables 2 and 3 . In detail, 12 out of 21 (57%) of these variants have been reported as novel variants absent in healthy controls (Table 2) in the original studies. The remaining 9 variants (43%) have been reported as either rare or common variants because they have also been identified in ≥1 control subjects ( Table 3 ). The genotype frequency of these 9 variants (Table 3) , the 2 autosomal recessive variants in CASQ2, and the 2 ANK2 variants ( Table 2) were not included in variant comparisons. The 10 novel putative disease-causing variants were identified in 41 out of 6131 subjects in the ESP population ( Table 2 ). The 6131 subjects comprise the average number genotyped for each variant in the ESP. Assuming that each of the 41 subjects harbors only 1 putative disease-causing variant, the genotype prevalence of CPVT in the ESP population is 1:150. However, because it cannot be excluded that a single subject carries >1 of the 41 variants, the genotype prevalence could theoretically be lower, and, to be conservative, we therefore report a prevalence of up to 1:150.
None of the CPVT-associated variants in CALM1 and TRDN were identified in the ESP population. See Table II in the Appendix in the online-only Data Supplement for further details.
Prediction Analysis
To be conservative with the in silico prediction analysis, the prediction results for the variants shown in Table 3 , the 2 autosomal recessive variants in CASQ2 in Table 2 , the 2 CPVT phenocopy variants in ANK2 in Table 2 , and the 7 variants in KCNJ2 in Table II in the online-only Data Supplement were not included in our the prediction analysis. Furthermore, we classified the PolyPhen-2 predictions of probably damaging and possibly damaging as damaging. In this setting, Poly-Phen-2 predicted 92% of the ESP-negative variants as damaging compared with 70% of the ESP-positive variants (P=0.05). The SIFT software predicted 75% of the ESP-negative variants to be damaging compared with 40% of the ESP-positive variants (P=0.024). The conservation predictions showed that 98% ESP-negative variants were conserved compared with 90% of the ESP-positive variants (P=0.208). The Grantham Score predictions showed that 50% of the ESP-negative variants were damaging compared with 30% of the ESP-positive variants (P=0.330). Using the Giudicessi et al 20 agreement of ≥3 in silico tool predictions showed 83% of the ESP-negative variants as damaging compared with 50% of the ESP-positive variants (P=0.021; Figure 1 ). For more details, see the Appendix in the online-only Data Supplement.
Discussion
This is the first study to review the genetic background noise in CPVT based on the prevalence of previously reported CPVT-associated genetic variants in the ESP. In addition, we added prediction analysis to all CPVT-associated variants.
ESP-Positive Variants
CPVT has an estimated prevalence of 1:10 000. In the ESP, missense variants previously associated with CPVT were identified in 41 of 6131 participants, corresponding to a CPVT genotype prevalence of up to 1:150. This is a large overrepresentation of CPVT-associated variants; hence, it is likely that many of these variants are not the major/monogenic cause of CPVT. More likely some of these variants, without convincing family cosegregation, are either innocent bystanders or carrying only a small effect despite their rare occurrence. However, whether these variants lead to an increased susceptibility to CPVT cannot be ruled out and should be investigated in larger cohort studies. Additionally, functional studies are needed to define the specific role of these variants.
The ESP data revealed that RYR2 is a polymorphic gene, which is in contrast to what has been considered previously. It is well established that variants in cardiac RYR2 account for up to two thirds of CPVT cases. Given the rare prevalence of CPVT and the fact that the variations in RYR2 are inherited in a dominant manner, the a priori likeliness of finding any subjects in the ESP population with genetic defects causing CPVT is low. However, all the ESP-positive putative variants were identified in the RYR2 gene, which corresponded to a prevalence of CPVT1 up to 1:150 (41 out of 6131).
Leenhardt et al suggest that most of the carriers of a single CASQ2 variant are healthy. 2 Others have suggested that CPVT2 has a mild phenotype and a lower penetrance compared with CPVT1. [21] [22] [23] Interestingly, using the Giudicessi et al agreement of ≥3 in silico prediction tools, 60% of all CPVT2 variants known today were predicted to be benign. However, the CPVT2 variants are thought to be inherited in an autosomal recessive manner. Therefore, we cannot make any final conclusions on the pathogenicity of specific variants unless they are found to be homozygous for disease-causing alleles. Therefore, ESP-positive variants in CASQ2 have not been accessed in this study ( Table 2) .
Contrary to the CASQ2 gene, it is well known that RYR2 has 3 regional hot spots where unique CPVT variants reside. Several variants in these regions have frequently been identified in patients with CPVT (n≥2). These variants were not found in the ESP and therefore may be considered as true disease-causing variants ( Table 4) .
Future functional studies on these variants may improve drug targeting and pharmacogenetic approaches.
In the ESP population, we also identified 9 rare and common CPVT-associated variants also found in healthy control subjects of the original studies ( Table 3 ). The prevalence of these variants and the variants in CASQ2 and ANK2 (Table 2) have not been included in the calculations in the present study, and this conservative approach essentially strengthens our conclusion. Interestingly, none of the rare and common CPVT-associated variants previously found in healthy controls (Table 3) were was predicted to be damaging by the agreement of ≥3 in silico tools. Nevertheless, these variants have been reported to be associated with CPVT in the HGMD and FSM Table 2 databases. No study has, to the best of our knowledge, sought to investigate whether the minor allele frequencies of CPVT1 variants differ significantly among patients and healthy control subjects. Therefore, the role of these variants as susceptibility variants or modifiers cannot be ruled out but needs to be investigated. In accordance with this, Laitinen et al 24 reported that the frequencies of T66A (rs4074536) and V76M (rs10801999) polymorphisms in CPVT2 probands were not significantly different from those in healthy controls and suggested that neither seemed to be associated with risk of CPVT2. A functional study revealed that T66A (rs4074536) shared characteristics with wild type, and that the V76M (rs10801999) variant showed significantly altered Ca 2+ -binding and polymerization behavior. 25 Further studies are needed to characterize the role of these variants in the pathogenesis of CPVT.
. ESP Genotype Frequencies and In Silico Predictions: Variants Previously Identified in Patients* With CPVT and Reported to be Absent in Healthy Controls
To date, there is no systematic screening of ANK2 and KCNJ2 genes in CPVT patients, and these 2 genes have been associated with other arrhythmogenic disorders that resemble the classic description of CPVT and are known as CPVT phenocopies. 5 However, KCNJ2 testing should be considered in the CPVT suspected patient with a negative RYR2 testing, abundance of complex ventricular ectopy present on 24-hour ambulatory monitoring, characteristic U waves, and in the absence of facial/skeletal stigmata. 5, 6 Recently, Nyegaard et al 26 added a new gene (CALM1) to the CPVT-associated gene panel (CPVT4; Table 1 and Table  II in the online-only Data Supplement). Their study suggests that further molecular testing is warranted to identify the involvement of other genes, which may also provide a better differential diagnosis between patients with, for example, atypical LQTS and CPVT. 16, 27 
ESP Population as a Representation of the General Population
We have previously found and described inclusion and exclusion criteria for 9 of the populations used in the ESP. [9] [10] [11] None of the cohorts specifically included subjects with channelopathies and ≥2 cohorts excluded patients with heart diseases.
The ESP is based on studies mainly representing the general population, and no CPVT cohort has specifically been included. The inclusion age of ESP subjects is 18 to 79 years. Because of the high penetrance of CPVT (71%-83%), mean age of onset (8 years), and a mortality rate of 30% to 50% before 35 years for untreated patients, it is unlikely that the ESP population contains any patients with CPVT, diagnosed or not. 1, 28 Thus, it is highly unlikely that the ESP population has a large overrepresentation of patients with CPVT (up to 1:150) compared with the low prevalence in the general population (1:10 000).
Recently, in 3 studies of inherited heart diseases, we established that the prevalences of 13 variants genotyped in Northern European control cohorts with no history of arrhythmias or other cardiac diseases were comparable with those of the ESP. [9] [10] [11] These results support the notion that the ESP population consists of individuals representative of the general population with regard to the phenotypes in question. 
Prediction Analysis
Tester et al 27 have emphasized the necessity of cosegregation and functional data in interpretation of genetic test results and claim that without these data a variant has a low probability of pathogenicity. Notably, <15% of variants summarized by Medeiros-Domingo et al 16 have been functionally studied. Therefore, interpretation of genetic testing results, especially in the setting of insufficient or inconclusive clinical evidence of disease, must be done with considerable caution. Accordingly, Giudicessi et al 20 used the agreement of ≥3 in silico prediction tools for classification of pathogenicity of rare variants and revealed the importance of the synergistic use of multiple tools to improve the classification of variants. To emphasize our prediction analysis, we did not include the results of CPVT-associated variants previously found in healthy controls (Table 3 ) and the 2 autosomal recessive variants in CASQ2 ( Table 2 ). Using the Giudicessi et al method, we identified a significantly higher frequency of damaging CPVT-associated variants among the ESP-negative variants compared with the ESP-positive variants (P=0.019). This trend was seen in all in silico prediction tools used in this study (Figure) . See the Appendix in the online-only Data Supplement for prediction results for CPVT-associated variants not found in the ESP (Tables I and II in the online-only Data Supplement).
Perspective
Use of Databases
Clinicians must be cautious when searching publicly available databases listing disease-causing variants for the purpose of checking the implication of variants in CPVT. Both HGMD and FSM list variants as disease causing; however, some of these variants have been found in healthy controls. Accordingly, some rare variants in the RYR2 (V377M, Y2156C, E2183V, M2389L, V4010M, A4282V, and G4315E), observed only in healthy control subjects in the study by Medeiros-Domingo et al, 16 have been reported as CPVT1-associated variants in the FSM database (http://www.fsm.it/cardmoc/). 16 This might lead to confusion and consequences concerning family evaluations, especially for asymptomatic family members. These variants were not included in this study.
Genetic counseling should be based on clinical data, family history, bioinformatics, and functional characterization before the pathogenicity of the variant is affirmed. This is especially important with regard to risk stratification of asymptomatic family members because genetic counseling of these has psychological, economic, and quality of life consequences. Therefore, ESP could be a useful tool in establishing the true pathogenicity of rare variants; hence, clinical data on such cohorts need to be publicly available.
Consequences of Possible False-Positive Variations
Several studies suggest that β-blockers should be used for all clinically diagnosed CPVT patients and all family members with an RYR2 variant with no history of cardiac events, even after a negative exercise stress testing for prevention of primary manifestations such as sudden infant death syndrome and sudden cardiac death. 1, [29] [30] [31] [32] Thus, lifelong medication of relatives without any clinical symptoms could be the consequence of finding a false-positive variant in an index patient. In addition, possibly healthy individuals who carry a false-positive variant are advised to avoid competitive sports and other strenuous exercise and to visit their cardiologist at least annually. Thus, the false-positive variants also have physiological, psychological, and financial consequences.
An even worse scenario is if family members are counselled on the basis of not carrying a false-positive variant found in the index patient in situations where the true disease-causing variant has not been identified because this may have severe consequences for treatment, clinical advice, and follow-up.
Limitations
Failure to distinguish whether any CPVT-positive ESP subject harbors >1 CPVT-associated variant may overestimate the prevalence of individuals in the background population that carries a CPVT-associated variant. However, it has been reported that only 5.5% (4 out of 73) of RYR2 variantpositive cases carry multiple disease-associated variants. 16 Additionally, functional characteristics have only been reported for the minority of the CPVT-associated variants. Such data would undoubtedly be useful in interpretation of the possible pathophysiological involvement of these variants in CPVT.
Conclusions
We identified 10 previous novel putative CPVT variants in 41 subjects in a large exome database, which would correspond to a CPVT prevalence of up to 1:150. This questions the causality of some of these variants, suggesting that they are not the monogenic cause of the disease. Therefore, caution should be taken with regard to risk stratification based on previously published genetic variants in CPVT.
